Hydroxyurea and Thalidomide in Thalassemia patients
- Conditions
- Health Condition 1: D561- Beta thalassemia
- Registration Number
- CTRI/2022/12/048540
- Lead Sponsor
- DGAFMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Diagnosis of transfusion-dependent thalassemia
2. ECOG: 0 to 2 scores
3. Blood transfusion to maintain the Hb or level of Hb <9g/dl if not transfused
4. Sign an informed consent agreeing to the clinical trial participation
1. Patients with comorbidities like severe heart or lung diseases, liver dysfunction, renal dysfunction, malignancy, cerebrovascular disease, or other serious primary diseases
2. Patients allergic to the drug ingredients
3. Patients with any mental health problem
4. Patients had participated in other drug clinical trials in the past 1 month
5. Patients had a history of venous or arterial thrombosis
6. Childbearing age unwilling to use contraceptive measures
7. In certain circumstances the researchers determined it was not suitable for the research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method